Head and Neck Squamous Cell Carcinoma Market Size 2018-2026: Leading Players Like Merck & Co., Bristol-Myers Squibb Co., Eli Lilly, Taiho, AstraZeneca, Pfizer, Incyte, Tessa Therapeutics, Boehringer Ingelheim, CEL-SCI, Pierre Fabre
This report provides an in-depth insight of Head and Neck Squamous Cell Carcinoma Industry covering all important parameters including development trends, challenges, opportunities, key manufacturers and competitive analysis.
(EMAILWIRE.COM, July 09, 2018 ) The head and neck (HNC) cancer market is expected to experience significant growth between 2016 and 2026 within the seven major markets (US, France, Germany, Italy, Spain, UK and Japan). The main growth drivers will be attributed to the incorporation of immune-checkpoint inhibitors into the first-line recurrent/metastatic and locally-advanced disease treatment paradigms. Due to the high cost of immunotherapy regimens, this is expected to cause large growth within the head and neck cancer market.
Up until the approvals of Opdivo in the 7MM and Keytruda in the US during 2016 for the platinum-refractory recurrent/metastatic population, Erbitux was the only targeted agent ion the market, whilst the rest of the market was dominated by generic chemotherapy. Now that programmed cell death protein 1 (PD-1) inhibitors have penetrated into the second-line, label-expansions into earlier lines and in combinations with other immuno-oncology (IO) agents are expected during the forecast period. This will significantly expand the eligible population that can receive these premium-priced immunotherapies - The HNC competitive landscape is expected to experience a significant change, a new standard of care is predicted to be established in eight pipeline agents are expected to launch before 2026.
Get sample copy of this report@ http://orbisresearch.com/contacts/request-sample/2189669
Key Players:
Merck & Co.
Bristol-Myers Squibb Co.
Eli Lilly
Taiho
AstraZeneca
Pfizer
Incyte
Tessa Therapeutics
Boehringer Ingelheim
CEL-SCI
Pierre Fabre
Scope:
- Overview of HNC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized HNC therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HNC therapeutics market.
- Overview of HNC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized HNC therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HNC therapeutics market.
Inquiry before buying@ http://orbisresearch.com/contacts/enquiry-before-buying/2189669
Key Questions Answered
- How will the implementation of IO agents into earlier-lines of therapy affect the current treatment paradigm and which combinations are expected to have the greatest impact and highest chance of an approval?
- The head and neck cancer market is characterized by a number of unmet needs. What are the main unmet needs in this market? Will the pipeline drugs under development fulfil these needs?
- Eight late-stage pipeline agents are going to enter the head and neck cancer market from 2017 onwards. Will the late-stage drugs make a significant impact on the head and neck cancer market? Which of these drugs will have the highest peak sales, and why?
Reasons to buy:
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HNC market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HNC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Up until the approvals of Opdivo in the 7MM and Keytruda in the US during 2016 for the platinum-refractory recurrent/metastatic population, Erbitux was the only targeted agent ion the market, whilst the rest of the market was dominated by generic chemotherapy. Now that programmed cell death protein 1 (PD-1) inhibitors have penetrated into the second-line, label-expansions into earlier lines and in combinations with other immuno-oncology (IO) agents are expected during the forecast period. This will significantly expand the eligible population that can receive these premium-priced immunotherapies - The HNC competitive landscape is expected to experience a significant change, a new standard of care is predicted to be established in eight pipeline agents are expected to launch before 2026.
Get sample copy of this report@ http://orbisresearch.com/contacts/request-sample/2189669
Key Players:
Merck & Co.
Bristol-Myers Squibb Co.
Eli Lilly
Taiho
AstraZeneca
Pfizer
Incyte
Tessa Therapeutics
Boehringer Ingelheim
CEL-SCI
Pierre Fabre
Scope:
- Overview of HNC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized HNC therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HNC therapeutics market.
- Overview of HNC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized HNC therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HNC therapeutics market.
Inquiry before buying@ http://orbisresearch.com/contacts/enquiry-before-buying/2189669
Key Questions Answered
- How will the implementation of IO agents into earlier-lines of therapy affect the current treatment paradigm and which combinations are expected to have the greatest impact and highest chance of an approval?
- The head and neck cancer market is characterized by a number of unmet needs. What are the main unmet needs in this market? Will the pipeline drugs under development fulfil these needs?
- Eight late-stage pipeline agents are going to enter the head and neck cancer market from 2017 onwards. Will the late-stage drugs make a significant impact on the head and neck cancer market? Which of these drugs will have the highest peak sales, and why?
Reasons to buy:
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HNC market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HNC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results